The nootropics research category covers a structurally diverse set of compounds sharing a common area of investigation: modulation of cognitive function, neuroprotection, and neurochemical signalling. For Australian researchers sourcing nootropic compounds, understanding the distinct mechanisms of the four most-studied classes — the classical racetam family, Noopept, and the synthetic peptide nootropics Semax and Selank — is essential for study design and compound selection.
This article provides a structured research comparison for laboratory reference purposes only.
What Are Nootropics? Research Context
The term “nootropic” was coined in 1972 by neuropsychopharmacologist Corneliu Giurgea, who described compounds that enhance learning and memory while being neuroprotective and having low toxicity. In contemporary research, the classification covers a wide range of compounds with overlapping but distinct mechanisms — from the classical racetam family (Piracetam and its structural descendants) to peptide-based compounds like Semax and Selank derived from endogenous neuropeptide sequences.
The Racetam Family
Racetams are defined by a shared 2-oxo-pyrrolidine ring structure. All racetams exert at least some of their effects through positive modulation of AMPA-type glutamate receptors, enhancing glutamatergic transmission and synaptic plasticity.
Piracetam — The Original
Piracetam was the first synthesised nootropic (Giurgea, 1964) and has the most extensive published research dataset of any nootropic compound, with over 20 controlled trials in cognitive impairment populations. Primary proposed mechanisms include AMPA receptor positive modulation and enhancement of neuronal membrane fluidity and phospholipid metabolism. It is the least potent racetam per milligram but the most pharmacokinetically characterised.
Aniracetam
A fat-soluble racetam with AMPA modulation plus proposed 5-HT₂A receptor interaction, giving it a distinctive anxiolytic component alongside cognitive effects. More potent than piracetam per milligram in preclinical models. The 5-HT₂A interaction differentiates it mechanistically from piracetam and is the proposed basis for its anxiolytic signal in animal studies.
Oxiracetam
AMPA modulator with additional NMDA receptor activity; preclinical evidence for enhanced spatial memory consolidation and acetylcholine turnover in hippocampal regions. More selective for hippocampal cognition-related pathways than piracetam in animal models.
Phenylpiracetam
Piracetam derivative with an added phenyl group that confers a higher stimulant profile, proposed to involve dopamine and noradrenaline activity in addition to AMPA modulation. Shorter duration of action; used in research models examining stimulant-cognition interactions.
Noopept (GVS-111)
Noopept is a dipeptide-derived synthetic compound — structurally distinct from the racetam class despite frequent misclassification. It lacks the defining 2-oxo-pyrrolidine ring and functions as a prodrug: after absorption, it is metabolised to cycloprolylglycine, a naturally occurring endogenous dipeptide in the brain.
Mechanisms
- Positive AMPA receptor modulation (via cycloprolylglycine metabolite)
- PHD2 enzyme inhibition → HIF-1α pathway activation → broad neuroprotective gene expression
- Upregulation of NGF (Nerve Growth Factor) and BDNF (Brain-Derived Neurotrophic Factor) mRNA in hippocampus and cortex
- Modulation of NMDA receptor expression in chronic dosing models
Noopept’s effective research dose range is substantially smaller than piracetam (microgram vs milligram scale) due to its prodrug activation mechanism and high CNS bioavailability. The NGF and BDNF upregulation distinguishes it from classical racetams, which do not consistently produce neurotrophic factor changes.
Semax (ACTH Fragment Analogue)
Semax is a synthetic heptapeptide analogue of the adrenocorticotropin hormone (ACTH) fragment 4–7, with a C-terminal Pro-Gly-Pro extension that enhances stability and CNS penetration. Developed by the Institute of Molecular Genetics in Russia, Semax has been registered as a drug in Russia since the 1990s for stroke recovery and cognitive enhancement in impairment states.
Mechanisms
- BDNF upregulation — Semax consistently produces rapid, robust increases in BDNF expression in the hippocampus and frontal cortex in animal models; this is its most replicated mechanism
- VEGF upregulation and angiogenesis — similar to BPC-157 and TB-500, Semax promotes cerebrovascular angiogenic signalling
- Dopaminergic and serotonergic modulation — influences dopamine D1/D3 receptor expression and serotonin turnover in cortical regions
- Cholinergic activity — increased acetylcholine release in prefrontal and hippocampal regions
Clinical Data
Semax has the most extensive clinical research of any nootropic peptide, including a 110-patient randomised trial in stroke rehabilitation demonstrating significant improvements in neurological recovery markers compared to control. It is licensed and used clinically in Russia and several CIS countries.
Selank (Tuftsin Analogue)
Selank is a synthetic heptapeptide analogue of Tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory tetrapeptide. Developed alongside Semax at the Institute of Molecular Genetics in Russia, Selank is primarily researched for anxiolytic and cognition-enhancing properties through a GABAergic mechanism.
Mechanisms
- GABA-A receptor positive modulation — benzodiazepine-like anxiolytic mechanism without the addiction potential and cognitive impairment seen with classical benzodiazepines in preclinical models
- BDNF upregulation — particularly in hippocampal regions; lower magnitude than Semax but consistent
- Enkephalin stabilisation — inhibits enkephalin-degrading enzymes, prolonging endorphin signalling
- Anxiety reduction with maintained cognition — key differentiator from benzodiazepines in animal models
Semax + Selank in Combined Research Models
The Semax/Selank combination is studied in models requiring simultaneous neuroplasticity enhancement (Semax via BDNF) and anxiety/neural noise reduction (Selank via GABA-A modulation). This combination addresses two distinct CNS pathways that most single-compound protocols cannot simultaneously target, making it of interest for research into stress–cognition interaction models.
Research Comparison Summary
| Compound | Class | Primary Mechanism | Human Data | Key Research Application |
|---|---|---|---|---|
| Piracetam | Racetam | AMPA modulation, membrane fluidity | Most extensive of any nootropic | Cognitive decline, dementia models |
| Aniracetam | Racetam | AMPA + 5-HT₂A | Limited | Anxiolytic + cognitive combination |
| Oxiracetam | Racetam | AMPA + NMDA + hippocampal ACh | Limited | Spatial memory consolidation |
| Phenylpiracetam | Racetam derivative | AMPA + dopaminergic/noradrenergic | Very limited | Stimulant-cognition interaction |
| Noopept | Dipeptide prodrug | Cycloprolylglycine → AMPA + HIF-1 + BDNF/NGF | Limited | Neuroprotection, memory consolidation |
| Semax | Peptide (ACTH analogue) | BDNF upregulation, dopaminergic, VEGF | Extensive (Russia); 110-pt RCT | Neuroprotection, stroke recovery models |
| Selank | Peptide (Tuftsin analogue) | GABA-A modulation, BDNF, enkephalin | Moderate (Russia) | Anxiolytic + cognitive combination |
Sourcing Nootropic Research Compounds in Australia
PureRawz Australia supplies all major nootropic research compounds — including Noopept, Semax, Selank, Piracetam, Aniracetam, Oxiracetam, and the broader racetam family — independently tested at ≥99% purity with batch-specific Certificates of Analysis.
Browse nootropic research compounds →
Frequently Asked Questions
What is the difference between Semax and Selank in research?
Semax is a heptapeptide ACTH analogue that primarily works via BDNF upregulation, dopaminergic modulation, and angiogenic signalling. It is the stronger compound for pure cognitive enhancement endpoints. Selank is a Tuftsin analogue that primarily works via GABA-A positive modulation and BDNF upregulation, with a stronger anxiolytic signal. They are studied in combination for models requiring both neuroplasticity enhancement (Semax) and anxiety/neural noise reduction (Selank) simultaneously.
Is Noopept a racetam?
No. Despite frequent misclassification, Noopept is not a racetam. It lacks the defining 2-oxo-pyrrolidine ring of the racetam class and has a distinct mechanism: it is a dipeptide prodrug metabolised to cycloprolylglycine, which then modulates AMPA receptors and activates the HIF-1 pathway, while also upregulating NGF and BDNF — mechanisms not shared by classical racetams.
Which nootropic compound has the most human clinical research data?
Piracetam has the most extensive human clinical dataset of any nootropic compound, with over 20 controlled trials in cognitive impairment and dementia populations. Among peptide nootropics, Semax has the most human data, including a 110-patient randomised stroke rehabilitation trial and decades of clinical use in Russia.
Are nootropic research compounds legal to purchase in Australia?
Most nootropic compounds — including Noopept, Semax, Selank, and the racetam family — are not scheduled under the TGA Poisons Standard and are legally available in Australia for laboratory and research use. Researchers should verify the scheduling status of any specific compound and confirm institutional compliance requirements before commencing research.
What is the primary mechanism of Semax in neurological research models?
Semax’s most replicated mechanism in animal and in vitro models is rapid and robust upregulation of BDNF (Brain-Derived Neurotrophic Factor) in hippocampal and cortical regions. It also modulates dopaminergic signalling, promotes cerebrovascular angiogenesis via VEGF, and enhances cholinergic activity in prefrontal and hippocampal areas.
For laboratory and research use only. Not for human or veterinary consumption. Nothing in this article constitutes medical advice.
